Amylyx Pharmaceuticals, Inc.
AMLX
Rang în acțiuni
#4618
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Preț acțiune
$26.28
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$3.30B
Schimbare (1 zi)
-4.95%
Schimbare (1 an)
75.79%
Țară
US
Tranzacționează Amylyx Pharmaceuticals, Inc. (AMLX)
Categorie
Healthcare
EPS pentru Amylyx Pharmaceuticals, Inc. (AMLX)
EPS la data de June 2026 TTM: $-1.41
Conform celor mai recente rapoarte financiare și prețului acțiunilor Amylyx Pharmaceuticals, Inc., EPS-ul actual al companiei (TTM) este $-1.41. La sfârșitul anului 2023, compania avea un EPS de $0.73 o creștere față de EPS-ului din 2022, care a fost de $-2.98.
Istoricul EPS pentru Amylyx Pharmaceuticals, Inc. din 2019 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
